Hannah Choe is a Hematology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 219 publications with 2,274 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave Fl 5
Columbus, OH 432101240
Telephone
614-293-3196Provider last certified this registry record 23 Dec 2020.
Clinical trials
- Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Sponsor: Hannah Choe, MD
- High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI US SERVICES INC.Program year20251 payment
- Incyte CorporationProgram year20252 payments
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
Ohio State University
FY2025$415,000R01CA252469 - Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
Ohio State University
FY2024$394,251R01CA252469 - Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
Ohio State University
FY2023$406,701R01CA252469
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Journal of Hematology & Oncology
2025 - Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ricardo Carrau, MD
The Ohio State University Comprehensive Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD, PhD
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”